Global Health Metricswww.thelancet.com   Vol 392   November 10, 2018  185716 Ahmed S, Tunçalp Ö. Burden of obstetric fistula: from 
measurement to action. 
Lancet Glob Health 2015; 3: e243–44.
17 Wall LL. Obstetric fistula is a “neglected tropical disease”. PLoS Negl T
rop Dis 2012; 6: e1769.
18 Higashi H, Barendregt JJ, Kassebaum NJ, Weiser TG, Bickler SW
, 
Vos T. Surgically avertable burden of obstetric conditions in low- and middle-income regions: a modelled analysis. BJOG Int J Obstet Gynaecol 2014; 122: 228–36.
19
 GBD 2017 Mortality Collaborators. Global, regional, and national age-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global B
urden of Disease Study 2017 . Lancet 2018; 
392: 1684–735.
20 Stevens GA, Alkema L, Black RE, et al.  Guidelines for accurate and
 
transparent health estimates reporting: the GATHER statement. Lancet 2016; 388: e19–23.
21
 United Nations Population Division. Department of Economic and S
ocial Affairs. Population. https://www.un.org/development/desa/
en/key-issues/population.html (accessed May 6, 2017).
22 US Census Bureau. International Data Base (IDB). https://www.census.gov/programs-surveys/international-programs/about/idb.html (accessed M
ay 6, 2018).
23 Salomon JA, Haagsma JA, Davis A, et al.  Disability weights for the
 
Global Burden of Disease 2013 study. Lancet Glob Health 2015; 3: e712–23.
24
 GBD 2017 Population and Fertility Collaborators. P
opulation and 
fertility by age and sex for 195 countries and territories 1950–2017: a systematic analysis for the Global Burden of Disease 2017 . Lancet 2018; 392: 1995–2051.
25
 GBD 2017 Cause of Death Collaborators. Global, regional, and national age-specific and sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
. Lancet 2018; 
392: 1736–88.
26 Mckee S. Rethinking development and health: findings from the Global Burden of Disease Study
. Seattle, WA: Institute for Health 
Metrics and Evaluation, 2016.
27 The Lancet. The global HIV /AIDS epidemic—progress and challenges. Lancet 2017; 
390: 333.
28 Locarnini S, Hatzakis A, Chen D-S, Lok A. Strategies to control hepatitis B: Public policy
, epidemiology, vaccine and drugs. 
J Hepatol 2015; 62:  S76–86.
29 Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. H
epatology 2012; 
57: 2164–70.
30 Hill A, Cooke G. Hepatitis C can be cured globally
, but at what cost? 
Science 2014; 345:  141–42.
31 Kamal-Yanni M. Hepatitis C drug affordability. 
Lancet Glob Health 
2015; 3:  e73–74.
32 Attard SM, Herring AH, Zhang B, Du S, Popkin BM, G
ordon-larsen P. Associations between age, cohort, 
and urbanization with Sbp and Dbp in China: a population-based study across 18 years. J Hypertens 2015; 33:  948–56.
33
 Song L, Shen L, Li H, et al.  Height and prevalence of hypertension in
 
a middle-aged and older Chinese population. Sci Rep 2016; 6:  39480.
34 Muntner P, Gu D, Wu X, et al
. Factors associated with hypertension 
awareness, treatment, and control in a representative sample of the chinese population. Hypertension 2004; 43:  578–85.
35
 Ford ES, Ajani UA, Crof
t JB, et al. Explaining the decrease in US 
deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 2388–98.
36
 Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. 
Lancet 2011; 
378: 804–14.
37 Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary 
prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American H
eart Association and American College of 
Cardiology Foundation. Circulation 2011; 124:  2458–73.
38 Eckel RH, Jakicic JM, Ard JD, et al.  2013 AHA/ACC guideline
 
on lifestyle management to reduce cardiovascular risk: a report 
of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S76–99.39
 Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC
/AHA 
guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:  S1–45.
40
 Perk J, De Backer G, Gohlke H, et al.
 European Guidelines on 
cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:  1635–701.
41
 Daya MR, Schmicker RH, Zive DM, et al. Out-of
-hospital cardiac 
arrest survival improving over time: results from the Resuscitation Outcomes Consortium (ROC). Resuscitation 2015; 91:  108.
42
 Girotra S, Nallamothu BK, Spertus JA, Li Y , Krumholz HM, Chan PS. T
rends in survival after in-hospital cardiac arrest. 
N Engl J Med 2012; 367:  1912.
43 Berger S. Survival from out-of-hospital cardiac arrest: are we beginning to see progress? 
J Am Heart Assoc 2017; 6:  e007469.
44 American College of Cardiology. Despite overall in-hospital cardiac arrest survival improvement, lower  survival on nights, weekends persists. https://www
.acc.org/about-acc/press-releases/2018/01/22/ 
14/16/despite-overall-in-hospital-cardiac-arrest-survival-improvement-lower-survival-on-nights-weekends-persists (accessed May 7, 2018).
45
 Malhotra A, Rakhit R. Improving the UK’s performance on survival after cardiac arrest. 
BMJ 2013; 347:  f4800.
46 Sasson C, Rogers MAM, Dahl J, Kellermann AL. Predictors of survival from out-of
-hospital cardiac arrest: a systematic review and 
meta-snalysis. Circ Cardiovasc Qual Outcomes 2010; 3:  63–81.
47 Mora S, Wenger NK, DeMicco DA, et al
. Determinants of residual 
risk in secondary prevention patients treated with high- versus low-dose statin therapy clinical perspective: the treating to new targets (TNT) study. Circulation 2012; 125:  1979–87 .
48
 Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review
. JAMA 2003; 290:  86.
49 Heaton RK, Grant I, McSweeny AJ, Adams KM, P
etty TL. 
Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med 1983; 143:  1941–47 .
50
 Eaton T, Lewis C, Young P, Kennedy Y
, Garrett JE, Kolbe J. 
Long-term oxygen therapy improves health-related quality of life. Respir Med 2004; 98:  285–93.
51
 Clini E, Vitacca M, Foglio K, Simoni P, Ambrosino N.
 
Long-term home care programmes may reduce hospital admissions in COPD with chronic hypercapnia. Eur Respir J 1996; 9: 1605–10.
52
 Tanni SE, Vale SA, Lopes PS, Guiotoko MM, G
odoy I, Godoy I. 
Influence of the oxygen delivery system on the quality of life of patients with chronic hypoxemia. J Bras Pneumol 2007; 33:  161–67 .
53
 Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? Eur Respir J 2002; 
20: 38–42.
54 Weitzenblum E, Oswald M, Apprill M, Ratomaharo J, K
essler R. 
Evolution of physiological variables in patients with chronic obstructive pulmonary disease before and during long-term oxygen therapy. Respir Int Rev Thorac Dis 1991; 58:  126–31.
55
 Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev
 2006; 1: CD002733.
56 Wongsurakiat P, Maranetra KN, Wasi C, K
ositanont U, 
Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125:  2011–20.
57
 Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. 
Ann Intern Med 1999; 
130: 397–403.
58 Xu J, Zhang Y , Qiu C, Cheng F. Global and regional economic costs of dementia: a systematic review. 
Lancet 2017; 390:  S47 .
59 Xu J, Wang J, Wimo A, F
ratiglioni L, Qiu C. The economic burden 
of dementia in China, 1990–2030: implications for health policy. Bull World Health Organ 2017; 95:  18–26.